Daiichi Sankyo Co., Ltd. and Eli Lilly plan to begin a large Phase III trial in 2Q2008 to compare prasugrel, an investigational oral antiplatelet agent, against Bristol-Myers Squibb’s clopidogrel (Plavix/Iscover) in medically managed patients with acute coronary syndrome (ACS), a group of common heart conditions that includes unstable angina (chest pain) and heart attacks. The multi-center, double-blind, randomized trial will include approximately 10,000 patients in 35 countries. TRIL...